PharmTech News

Caroline Hroncich was associate editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International from 2015 to 2017.

Articles

Mylan reached a $485-million settlement with the Department of Justice over questioned raised about the Medicaid rebate classification of EpiPen.

Mylan Reaches Settlement with Department of Justice

Results from the Phase III POLLUX trial with Janssen’s Darzalex showed that the drug was effective at reducing disease progression in patients with relapsed or refractory multiple myeloma.

Darzalex Combination Shows Promise as Multiple Myeloma Treatment

The companies are collaborating on the commercialization of two biosimilar candidates in the US and Canada.

Teva and Celltrion Partner on Biosimilar Commercialization

Xellia added laboratory space and personnel in Zagreb, Croatia to work on anti-infective products that combat the antimicrobial resistance problem.

Xellia Pharmaceuticals Expands R&D in Croatia

Tosoh Bioscience adds TOYOPEARL Sulfate-650F, a strong cation exchange resin that exhibits high salt tolerance, to its process media product line.

Cation Exchange Resin Achieves Higher Dynamic Binding Capacity

Bio-Rad Laboratories’ Nuvia IMAC Resin, an immobilized metal affinity chromatography resin, is optimized for use from laboratory-scale through pilot studies to process-scale manufacturing.

Immobilized Metal Affinity Chromatography Resin

The Phase III trial examined guselkumab compared with a placebo and Humira at treating moderate-to-severe plaque psoriasis.

Guselkumab Superior to Humira in Phase III Trial

Allergan entered into a licensing agreement with AstraZeneca for MEDI2070, an anti-IL-23 monoclonal antibody in phase IIB development for the treatment of patients with moderate-to-severe Crohn’s disease.

Allergan Enters into Licensing Agreement with AstraZeneca

The new company will focus on R&D of cancer treatments.

Carrick Therapeutics Launches in Europe

ViraTherapeutics will develop its VSV-GP therapy alone and in combination with other therapies.

Bio/Pharma News